Anna Engström holds a PhD in infection biology/medical science from the Karolinska Institute, Stockholm, Sweden as well as an Engineering degree in molecular biotechnology from Uppsala University, Uppsala, Sweden. She also studied Engineering during one year at the University of Sydney, Sydney, Australia.

Her academic work has focused on drug-resistant tuberculosis (TB), the main part of the work was spent on developing molecular methods (based on padlock probes, sequencing methods) for rapid detection of drug-resistant TB, but she has also studied drug-resistance mechanisms, persistence, and epidemiology of drug-resistant TB. After completing a Swedish Research Council funded post doctoral fellowship at the Research Center Borstel in Germany. She works as a team leader for the laboratory at Clinical Genomics, Science for Life Laboratory, Stockholm, Sweden.

She works with bringing the latest next generation sequencing methods into Swedish healthcare and within the national initiative Genomic Medicine Sweden. Anna has previously also worked at the start up companies Vironova AB, Sweden and Mutabilis SA, France with viral and microbial drug development and detection.